pancreatic cancer pancreatic ductal adenocarcinoma
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: To be eligible to participate in this study, a subject must meet all the following criteria: • Histological or cytological (Bethesda 5 or 6) confirmed PDAC, as indicated by a definite cytology/histology report. • Scheduled for surgical removal of the pancreatic tumour. • Age >= 18 years. • Provision of written informed consent.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: • Diagnosis of immunodeficiency. • Received systemic steroid therapy or any other form of immunosuppressive therapy within 14 days before the screening. The following are exceptions to this criterion: o Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection). o Systemic corticosteroids. o Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are to identify patient-specific neoantigens from PDAC organoids and their immunogenicity and to conduct comprehensive oncologic, molecular and immunological analyses, including but not limited to RNA-based immune infiltration analysis, DNA damage repair analysis, single-cell sequencing, TCR sequencing, and spatial biology analysis. | — |
Primary
| Measure | Time frame |
|---|---|
| The main study endpoints are identifying patient-specific neoantigens from PDAC tumour material, evaluating the feasibility and efficacy of our peptide production laboratory in synthesising the predicted neoantigens as peptides and testing their in vitro immunogenicity to elicit tumour-specific T cells. | — |
Countries
Netherlands
Outcome results
None listed